Search research articles
Contact Us
Filters
Showing results (211-220 of 219) with videos related to
Page
of 22
Sort By:
You have reached the last page of results.
This site can display upto 219 results.
ESMO Open
|
November 19, 2025
PARPi and myeloid neoplasms; the Italian MITO-MaNGO experience based on a multicentric survey
M Turinetto, C Marchetti, G Scandurra, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 16, 2024
ENGOT-en11/GOG-3053/KEYNOTE-B21: a randomised, double-blind, phase III study of pembrolizumab or placebo plus adjuvant chemotherapy with or without radiotherapy in patients with newly diagnosed, high-risk endometrial cancer
T Van Gorp, D Cibula, W Lv, et al.
ESMO Open
|
September 26, 2022
Alternative academic approaches for testing homologous recombination deficiency in ovarian cancer in the MITO16A/MaNGO-OV2 trial
E D Capoluongo, B Pellegrino, L Arenare, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 11, 2025
Durvalumab with carboplatin/paclitaxel and bevacizumab followed by durvalumab and bevacizumab with or without olaparib maintenance in newly diagnosed non-BRCA-mutated advanced ovarian cancer
P Harter, F Trillsch, A Okamoto, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 21, 2023
Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial
I Ray-Coquard, A Leary, S Pignata, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 11, 2024
Efficacy of subsequent therapies in patients with advanced ovarian cancer who relapse after first-line olaparib maintenance: results of the PAOLA-1/ENGOT-ov25 trial
P Harter, C Marth, M-A Mouret-Reynier, et al.
British Journal of Cancer
|
February 9, 2023
INOVATYON/ ENGOT-ov5 study: Randomized phase III international study comparing trabectedin/pegylated liposomal doxorubicin (PLD) followed by platinum at progression vs carboplatin/PLD in patients with recurrent ovarian cancer progressing within 6-12 months after last platinum line
N Colombo, A Gadducci, J Sehouli, et al.
Circulation. Cardiovascular Imaging
|
November 15, 2022
Impact of Udenafil on Echocardiographic Indices of Single Ventricle Size and Function in FUEL Study Participants
Michael V Di Maria, David J Goldberg, Victor Zak, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 2, 2024
ESGO-ESMO-ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease
J A Ledermann, X Matias-Guiu, F Amant, et al.
Page
of 22
Search research articles
Search
Showing results (211-220 of 219) with videos related to
Sort By:
Page
of 22
You have reached the last page of results.
This site can display upto 219 results.
ESMO Open
|
November 19, 2025
PARPi and myeloid neoplasms; the Italian MITO-MaNGO experience based on a multicentric survey
M Turinetto, C Marchetti, G Scandurra, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 16, 2024
ENGOT-en11/GOG-3053/KEYNOTE-B21: a randomised, double-blind, phase III study of pembrolizumab or placebo plus adjuvant chemotherapy with or without radiotherapy in patients with newly diagnosed, high-risk endometrial cancer
T Van Gorp, D Cibula, W Lv, et al.
ESMO Open
|
September 26, 2022
Alternative academic approaches for testing homologous recombination deficiency in ovarian cancer in the MITO16A/MaNGO-OV2 trial
E D Capoluongo, B Pellegrino, L Arenare, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 11, 2025
Durvalumab with carboplatin/paclitaxel and bevacizumab followed by durvalumab and bevacizumab with or without olaparib maintenance in newly diagnosed non-BRCA-mutated advanced ovarian cancer
P Harter, F Trillsch, A Okamoto, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 21, 2023
Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial
I Ray-Coquard, A Leary, S Pignata, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 11, 2024
Efficacy of subsequent therapies in patients with advanced ovarian cancer who relapse after first-line olaparib maintenance: results of the PAOLA-1/ENGOT-ov25 trial
P Harter, C Marth, M-A Mouret-Reynier, et al.
British Journal of Cancer
|
February 9, 2023
INOVATYON/ ENGOT-ov5 study: Randomized phase III international study comparing trabectedin/pegylated liposomal doxorubicin (PLD) followed by platinum at progression vs carboplatin/PLD in patients with recurrent ovarian cancer progressing within 6-12 months after last platinum line
N Colombo, A Gadducci, J Sehouli, et al.
Circulation. Cardiovascular Imaging
|
November 15, 2022
Impact of Udenafil on Echocardiographic Indices of Single Ventricle Size and Function in FUEL Study Participants
Michael V Di Maria, David J Goldberg, Victor Zak, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 2, 2024
ESGO-ESMO-ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease
J A Ledermann, X Matias-Guiu, F Amant, et al.
Page
of 22